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Receptor antagonistOur study aimed to associate IL-1β and IL-1RN polymorphisms with AD disease in comparison with elderly
control group from São Paulo — Brazil. We genotyped 199 Alzheimer's disease (AD) patients, 165 elderly
control and 122 young control samples, concerning VNTR (IL-1RN) and −511C>T and −31T>C (IL-1β)
polymorphisms. Our ﬁndings revealed that −511C/−31T/2-repetitions VNTR haplotype had a protective
effect for AD when compared to EC (p=0.005), whereas −511C/−31C/1-repetition VNTR haplotype was
associated as a risk factor for AD (p=0.021). Taken together, we may suggest that there is a relevant role
of IL-1 genes cluster in AD pathogenesis in this Brazilian population.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Alzheimer's disease (AD) is a progressive and neurodegenerative
disorder that causes loss of memory, mental confusion and several cog-
nitive disturbances. Sporadic cases frequently present late-onset disease
whereas familial cases usually show early-onset disease (Khachaturian,
1985; Kay, 1986). There are evidences that at least four genes are
involved in AD etiology: mutations in APP, PSEN1 and PSEN2 genes
have been well documented in the literature and ε4 allele of APOE is
considered an expressive risk factor for late-onset AD (Pericak-Vance
et al., 1991; Dursun et al., 2008; Feulner et al., 2010).
The inﬂammatory process also seems to contribute to AD. Cytokines
and other proteins associated to inﬂammation were found in AD
patients' brains. The interleukin 1 (IL-1) is a pro-inﬂammatory cytokine
usually produced in the brain by the microglia and seems to play an
important role in the AD pathogenesis (Kornman, 2006). In humans,a, Hemocentro, Famema, Rua
ília, São Paulo, Brazil. Tel.: +55
).
vier OA license.the interleukin 1 cytokine family consists of three genes located on
the long arm of chromosome 2 that encodes for IL-1α, IL-1β and the
interleukin 1 receptor antagonist (RN) in a region of approximately
430 kb (Grifﬁn et al., 2000). Each of these genes shows single nucleotide
polymorphisms (SNPs) that affect their expression by increasing either
the rate of mRNA synthesis or stability.
Some ﬁndings have shown a reduced liberation of the three prin-
cipal pro-inﬂammatory cytokines (IL-1, IL-6 and TNF) and a presence
of a down-regulation system of the outlying immune response in the
last phase of the disease has been proposed (Sala et al., 2003). IL1A
2,2 polymorphism has been identiﬁed as a risk factor in neuropathologi-
cally conﬁrmed AD patients from four centers in the United Kingdom
and United States (Nicoll et al., 2000). A strong association between
IL1A T/T genotype with early-onset AD disease has been reported in
188 patients from Centers for Memory Disorders in Northern Italy
(Grimaldi et al., 2000). Moreover, the combination of IL1A polymor-
phism with IL1B polymorphism at position +3953 (exon 5) increased
the risk factor and modulated the age-onset of AD (Sciacca et al., 2003).
In a Japanese-American cohort of 943 men from Honolulu–Asia
Aging Study, a signiﬁcant association between the IL1B −511C>T
and IL1RN polymorphisms with late-onset AD has been detected,
Table 1
Genotype distribution of −511C>T, −31T>C and VNTR polymorphisms and Hardy–




AD EC YC 2 (p)
−31T>C C/C 57 (28.9) 54 (33.2) 45 (38.1) 2.16
(p=0.142)C/T 93 (47.2) 81 (49.6) 48 (40.7)
T/T 47 (23.9) 28 (17.2) 25 (21.2)
Total 197 163 118
−511C>T C/C 38 (20.2) 24 (15.8) 24 (21.6) 1.613
(p=0.203)C/T 107 (56.9) 84 (55.3) 48 (43.2)
T/T 43 (22.9) 44 (28.9) 39 (35.2)
Total 188 152 111
VNTR 2/2 10 (5.3) 18 (11.8) 8 (7.2) 1.737
(p=0.188)1/2 73 (38.8) 54 (35.6) 36 (32.4)
1/1 105 (55.9) 80 (52.6) 67 (60.4)
Total 188 152 111
AD: Alzheimer's disease group; EC: elderly control group; YC: Young control group.
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(Yucesoy et al., 2006).
Controversial ﬁndings concerning the relationship between IL1B
polymorphisms and AD have been reported. A signiﬁcant association
of−511 TT genotype with late-onset AD has been reported in Taiwan
Chineses and in Italians (Grimaldi et al., 2000; Licastro et al., 2000;
Wang et al., 2005) while other studies did not reply these association
ﬁndings (Ehl et al., 2003; Ma et al., 2003; Ravaglia et al., 2006; Wang
et al., 2007). An association study of AD with IL-1β (−31T>C) in a
Chinese population did not detect an involvement of this polymor-
phism in late-onset AD pathogenesis (Ma et al., 2003).
The substitution as position IL-1β (−511C>T) in the promoter
region of IL-1β regulates the production of IL-1β and the in vitro
expression of C/C genotype carriers was lower than that of C/T or T/T
carriers (Santtila et al., 1998). This is consistent with the hypothesis
that an increase in IL-1β expression increases the rate of Aβ deposition
and cytokine-mediated inﬂammation in predisposed individuals.
In the present study, we investigated a possible association among
the interleukin 1 β (−511C>T and −31T>C) and the interleukin 1
receptor antagonist with late-onset AD and controls.
2. Materials and methods
2.1. Subjects
Peripheral blood samples were obtained from 199 AD patients,
165 elderly control (EC) and 122 young control (YC) individuals.
The three subject groups had similar ethnic origins, being 95% with
major European origin, 2.5%, with Japanese origin and 2.5% with
mixture origin. The mean age and standard deviation of the samples
were 75.31±7.92 years for AD group composed by 69 men and 130
women; 71.67±8.13 years for EC group composed by 55 men and
110 women and 20.76±1.63 for YC group composed by 42 men
and 80 women. AD patients were selected according to NINCDS-
ADRDA criteria for probable AD (Morris, 1993). Vascular dementia
was excluded by a Hachinski score of 5 or higher and by neuro-
imaging (Hachinski et al., 1975). Patients and controls were from
São Paulo City and all subjects gave informed consent to participate
in this study that was approved by the local ethics committee.
2.2. Genotyping
Genomic DNA was extracted from blood samples using QIAamp
DNA Blood Midi Kit QIAGEN™ (Qiagen, Germany), following manu-
facturer's instructions. Genotypes were determined by a polymerase
chain reaction (PCR) and restriction fragment length polymorphism
(RFLP).
2.2.1. IL1β −31T>C
The 240 base pairs (bp) fragment was ampliﬁed from genomic
DNA using the oligonucleotides ST 5′-AGAAGCTTCCACCAATACT -3′
and AC 5′-TAGCACCTAGTTGTAAGGA-3′ (22). PCR conditions involved
an initial denaturation of 94 °C/5 min followed by 27 cycles of 94 °C/
45 s, 53 °C/45 s, 72 °C/1 min and a ﬁnal extension period at 72 °C/
7 min. The ampliﬁcation products (240 bp) were digested with Alu1
(Fermentas, USA) and visualized in 3% agarose gel, stained with ethi-
dium bromide and analyzed on Alpha Imager 2200 (Alpha Innotech
Corporation™).
2.2.2. IL1β −511C>T
IL-1β (−511C>T) genotypes were determined with a PCR and
RFLP. The 189 bp fragment was ampliﬁed from genomic DNA using
the oligonucleotides F 5′-CTGCATACCGTATGTTCTCTGCC-3′ and R 5′-
GGAATCTTCCCACTTACAGATGG-3′ (23). PCR conditions involved an
initial denaturation of 94 °C/5 min followed by 30 cycles of 94 °C/
30 s, 60 °C/30 s, 72 °C/30 s and a ﬁnal extension period at 72 °C/5 min. The ampliﬁcation products (189 bp) were digested with AvaI
(Fermentas, USA) and visualized in 2% agarose gel, stained with ethi-
dium bromide and analyzed on Alpha Imager 2200 (Alpha Innotech
Corporation™).
2.2.3. IL1RN/VNTR
Fragments containing variable number of identical tandem repeat
of 87 bp were ampliﬁed using the primers ﬂanking the region: RNa 5′
TCCTGGTCTGCAGGTAA 3′ and RNb 5′ CTCAGCAACACTCCTAT 3′ (24).
Ampliﬁcation was performed under the following conditions: at
94 °C for 5 min; 40 cycles at 94 °C for 30 s, 60 °C for 30 s, 72 °C for
30 s, followed by one cycle at 72 °C for 5 min and cooling at 4 °C.
PCR products of 410 bp (allele 1, four repeats of the 86 bp region),
240 bp (allele 2, two repeats), 500 bp (allele 3, ﬁve repeats), 325 bp
(allele 4, three repeats) and 595 bp (allele 5, six repeats).
2.3. Statistical analysis
Allele frequencies were calculated by allele counting as described
by Emery (Emery, 1986). Hardy–Weinberg equilibriumwas evaluated
using χ2 test. To assess the association between allele and morbidity,
logistic regression analysis was performed, which consideredmorbid-
ity as a dependent variable and allele, age and sex as covariates in the
model. Odds ratios (OR) with 95% conﬁdence intervals (CI) were also
calculated using SPSS® 18.0. For VNTR polymorphism, only subjects
with genotypes 1/1, 1/2 and 2/2 were included in the analysis. For
genotype distributions only two groups: I/I and non-I/I (I/II+II/II)
genotypes were analyzed, due to the expected small number of sub-
jects. Linkage disequilibrium (LD) and haplotype association analysis
with morbidities were performed by Haploview software (Barrett
et al., 2005). Expectation–Maximization algorithm was used to esti-
mate haplotype frequencies and to verify the association between
haplotypes and morbidities. χ2 test was used to compare haplotypes
frequencies of cases and controls concerning the morbidities studied.
Statistical signiﬁcance was accepted at pb0.05.
3. Results
Genotype frequencies are presented in Table 1. Minor allele
frequencies of −511C>T, −31T>C and VNTR polymorphisms were
0.441, 0.455 and 0.257, respectively. All polymorphisms were within
the Hardy–Weinberg equilibrium in the whole population (df=1)
(Table 1).
Usinghaploview software,we observed that−511C>T and−31T>
C polymorphisms were in linkage disequilibrium (D′=0.7336) as well
Table 2
Haplotype association composed by IL1β −511C>T, −31T>C and VNTR polymor-
phisms between AD patients and Elderly Controls (EC).
−511C>T −31T>C VNTR Haplotype frequency OR (95% CI) p
C T 1 0.395 1.00 –
C T 2 0.073 0.26 (0.10–0.66) 0.005*
C C 1 0.072 2.42 (1.15–5.09) 0.021*
OR: odds ratio; CI: conﬁdence interval.
*p statistically signiﬁcant.
Table 3
Haplotype association composed by IL1b −511C>T, −31T>C and VNTR polymor-
phisms between AD patients and Young Controls (YC).
−511C>T −31T>C VNTR Haplotype frequency OR (95% CI) p
T C 1 0.402 1.00 –
T C 2 0.1507 1.80 (1.01–3.20) 0.05
C C 1 0.0777 2.81 (1.13–7.02) 0.028*
OR: odds ratio; CI: conﬁdence interval.
*p statistically signiﬁcant.
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0.336).
Tables 2 and 3 shows the haplotype composed by IL1 beta
−511C>T, −31T>C and VNTR polymorphisms frequencies, the
calculated Odds Ratio, the 95% Conﬁdence Interval and p value related
to comparison between AD patients and Controls . Thus, haplotype
−511C, −31T and VNTR2 showed a protective effect to AD in rela-
tion to Elderly Group. On the other hand, haplotype −511 C, −31 C,
VNTR1 has been considered a risk factor associated to AD in relation
do Elderly Group (p — 0.021, OR=2.41, 95% CI: 1.15–5.09) as well
as and in relation to Young controls (p — 0.028, OR=2.81, 95% CI:
1.13–7.02).
Table 4 indicates studies of the IL-1β −511C>T, −31C>T and
IL1RN polymorphisms/haplotypes and yours effects in AD.
4. Discussion
To our knowledge, there are no reports concerning association study
of IL1beta polymorphisms and haplotypes with AD in the Brazilian
population.
IL1 have been found to be related to susceptibility and to patho-
genic activities in the central nervous system and in many other
immune-mediated disorders, such as AD, Parkinson's, temporal lobe
epilepsy, schizophrenia, febrile convulsions and others (Mrak and
Grifﬁnbc, 2001). Each one of our studied polymorphisms of IL 1beta
did not show association with AD in relation to Elderly and YoungTable 4





Present study ** C ** T ** 2 – Ye
** C ** C ** 1 – Ye
Klimkowicz-Mrowiec et al. (2009) * C>T – – – No
Ma et al. (2003) * C>T * C>T – – No
Bosco et al. (2004) * C>T – * 2 – Ye
Bi et al. (2004) – – *1>2 – No
Forlenza et al. (2009) – – – ↑ Ye
Déniz-Naranjo et al. (2008) * T – – – Ye
Di-Bona et al. (2008) meta-analysis with
16 case–control study
* T – – – Ye
Wang et al. (2005) * T – – – YeControls, but our ﬁndings agreed partially with results from Polish
(Klimkowicz-Mrowiec et al., 2009) and Chinese populations where
IL1 beta (−511C>T) and (−31T>C) were not respectively associ-
ated with AD late-onset (Ma et al., 2003). Furthermore our ﬁndings
also partially agreed with those from Bosco et al. from an Italian
population (Bosco et al., 2004) who reported a protective effect of
allele 2 of IL1RN in 152 sporadic AD with dementia grade ≥6 accord-
ing to Reisberg score in relation to 136 age-matched controls.
Therefore we may suggest that this cluster is effectively involved
in AD late-onset pathogenesis in Brazilian population.
Probably IL1 up regulates expression and processing of APP, which
may inﬂuence A-beta load (beta-amyloid immunoreactivity) in the
brain of AD patients. It is also possible that the increased risk found
in previous studies could be caused by linkage disequilibrium with
other yet to be identiﬁed polymorphism in the IL-1 α and β cluster
in chromosome 2q14, present in some populations.
Likewise, IL-1β elevated the levels of sAPP in the culture medium
of primary neurons in a dose-dependent fashion (Liu et al., 2011). In
addition to inducing IL-1β expression and release, sAPP and Aβ also
stimulate microglia to release biologically relevant levels of glutamate
and its cooperative excitatory amino acid D-serine (Wu et al., 2004,
2007).
The imbalance in the IL-1β/IL-1RN ratio may result in elevated IL-
1 responses and a more severe inﬂammation. An increased serum
level of IL1 beta has been proposed as a stage marker of the ongoing
brain neurodegeneration since aging, mild cognitive impairment
and AD (Forlenza et al., 2009).
Excess production and secretion of IL-1β elevates neuronal ex-
pression of the precursors of each of the changes characteristic of
AD. These neurodegeneration-related precursors include β-amyloid
precursor protein (βAPP), which may lead in vivo to deposition of
Aβ (Sheng et al., 1996a, 1996b) and further induction of IL-1β
(Barger and Harmon, 1997); ApoE, which is present in plaques
(Sheng et al., 1996a, 1996b) and necessary for the accumulation of
Aβ deposits (Bales et al., 1999); and hyperphosphorylated tau
(Strittmatter et al., 1994), the principal component of neuroﬁbrillary
tangles. IL-1 also induces α-synuclein (Grifﬁn et al., 2006), the Lewy
body precursor.
Therefore, taking together our ﬁndings with those from literature
we can suggest that IL-1 gene cluster polymorphisms may play a rel-
evant role in the susceptibility to Alzheimer´s disease in Brazilians.Acknowledgements
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